Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$4.08
-$0.61(-13.01%)
At close: 4:00 PM EDT
$4.08
-$0.61(-13.01%)
Day’s Range― - ―
52-Week Range$3.98 - $13.69
Previous CloseN/A
Volume203.10K
Average Volume (3M)223.79K
Market Cap
$26.18M
Enterprise Value$26.56
Total Cash (Recent Filing)$55.08M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 06, 2026EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,388,223
10 Day Avg. Volume101,329
30 Day Avg. Volume223,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside1676.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.05
Revenue Forecast (FY)$29.79M
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ProgressFDA Fast Track plus supportive interim Phase 2 data materially raise the program’s regulatory and clinical visibility. Over 2–6 months this structurally improves trial momentum, increases partner interest, and can shorten development timelines, reducing long-term execution risk.
Partner Licensing And Upfront CashA $25M upfront regional licensing payment provides non-dilutive near-term funding and partner validation. Structurally this extends runway, funds clinical activity, and aligns incentives via milestones/royalties, lowering short-to-medium term financing pressure.
Gross Margins & Modest LeverageHigh gross profitability and relatively low debt give operational flexibility once revenue scales. Over months this structural strength means incremental revenues translate efficiently to gross profit, and limited leverage reduces bankruptcy risk during prolonged R&D cycles.
Bears Say
Chronic Cash BurnPersistently negative operating and free cash flow require repeated external funding or asset monetization. Structurally this raises dilution and financing risk over the next 2–6 months unless material milestone payments or revenue emerge to change the cash trajectory.
Sustained Large LossesOngoing large operating and net losses erode shareholder equity and limit reinvestment capacity. Over a medium horizon, persistent negative margins constrain the firm’s ability to self-fund development or scale operations without continued external capital or strategic partnerships.
No Commercial Revenue BaseAs a clinical-stage firm with no product sales, revenue depends on licensing, milestones, or future approvals. Structurally this creates perennial funding dependency and execution risk over months, making progress contingent on external financing or partner deals.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was $3.98 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is $26.18M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$2.21 earnings per share for the quarter, beating the consensus estimate of -$2.213 by $0.003.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate is -1.09.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 5,388,223 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -$2.21 in its last earnings report, beating expectations of -$2.213. Following the earnings report the stock price went up 6.799%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(1676.96% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
46.67%
Insiders
4.22% Mutual Funds
31.17% Other Institutional Investors
14.58% Public Companies and
Individual Investors